The U.S. Department of Justice and the FDA have taken steps to continue barring Actavis Totowa from manufacturing and distributing generic drugs. The actions were taken following a series of serious manufacturing problems which resulted in a nationwide Digitek recall earlier this year when double strength tablets were produced, and a subsequent recall that involved potential issues with over 65 different generic drugs. Continued

